Non-opioid Sedation Melt Pharmaceuticals focuses on patented non-intravenous and non-opioid sedation and analgesia for short-duration procedures, presenting a primary sales angle for outpatient and in-office settings seeking safer, opioid-free options.

Procedural Focus Target the large U.S. market for procedural sedation across more than 100 million medical procedures with MELT-300 and related formulations, highlighting potential to replace or supplement current sedation modalities.

Strategic Partnerships Recent collaborations with Catalent for Zydis fast-dissolve technology indicate readiness to scale formulations for ease of administration, creating co-development and licensing sales opportunities with global manufacturing partners.

Financial and Growth Readiness With a Series B of 24 million and total funding around 77 million, Melt is financially positioned to pursue rapid clinicalization, trials, and market entry activities that can drive near-term revenue opportunities.

Market Entry & Outreach Operate in a lean, clinical-stage footprint with a small employee base, which may enable agile pilot programs, early-adopter engagements, and targeted outreach to ambulatory surgical centers, ophthalmology practices, and other outpatient facilities seeking non-opioid sedation solutions.